New Zealand markets close in 6 hours 11 minutes

Hoth Therapeutics, Inc. (HOTH)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.0100-0.0600 (-5.61%)
At close: 04:00PM EDT
1.0200 +0.01 (+0.99%)
After hours: 06:40PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.0700
Open1.0100
Bid0.9545 x 200
Ask1.0600 x 100
Day's range0.9501 - 1.0300
52-week range0.5800 - 1.7900
Volume799,378
Avg. volume3,805,006
Market cap6.973M
Beta (5Y monthly)0.82
PE ratio (TTM)N/A
EPS (TTM)-1.5500
Earnings date11 Nov 2024 - 15 Nov 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.50
  • PR Newswire

    Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced encouraging preclinical results for its investigational Alzheimer's drug, HT-ALZ. In a recent study using Alzheimer's model mice treated with varying doses of HT-ALZ, significant reductions in astrocyte activity were observed in key areas of the brain, suggesting a potential link between reduced reactive astrocytes, and improved cognitive functi

  • Zacks

    Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient

    HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.

  • PR Newswire

    Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).